{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:45:31Z","timestamp":1786149931558,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.06.023","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:34:30Z","timestamp":1782952470000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia"],"prefix":"10.1016","volume":"211","author":[{"given":"Ting-Tai","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan Angel","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Yi Jin","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2026.06.023_bb0005","doi-asserted-by":"crossref","first-page":"549 e1","DOI":"10.1016\/j.ajog.2020.03.032","article-title":"Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms","volume":"223","author":"Clarke","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.023_bb0010","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jamainternmed.2018.2820","article-title":"Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis","volume":"178","author":"Clarke","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.023_bb0015","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of Type 2 diabetes with Cancer: a Meta-analysis with Bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2026.06.023_bb0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.019","article-title":"Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer","volume":"174","author":"Beavis","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.023_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejogrb.2024.09.030","article-title":"Risk factors for atypical hyperplasia or endometrial cancer in premenopausal women aged <\/= 45 years with abnormal uterine bleeding","volume":"302","author":"Jang","year":"2024","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.023_bb0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","article-title":"Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women","volume":"121","author":"ACOG committee opinion no. 557","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.023_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/AOG.0000000000004989","article-title":"Endometrial hyperplasia","volume":"140","author":"Ring","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.023_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/AOG.0000000000005641","article-title":"Predicting endometrial hyperplasia and endometrial cancer on recurrent abnormal uterine bleeding","volume":"144","author":"Veeranaraphanit","year":"2024","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.023_bb0045","article-title":"Surgery versus medical therapy for heavy menstrual bleeding","volume":"2016","author":"Marjoribanks","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5 Pt 1","key":"10.1016\/j.ygyno.2026.06.023_bb0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.AOG.0000124272.22072.6f","article-title":"Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial","volume":"103","author":"Learman","year":"2004","journal-title":"Obstet. Gynecol."},{"issue":"Supplement_1","key":"10.1016\/j.ygyno.2026.06.023_bb0055","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc26-S004","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association professional practice Committee for D.4","year":"2026","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ygyno.2026.06.023_bb0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"23","key":"10.1016\/j.ygyno.2026.06.023_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.023_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030466","article-title":"Exploring the role of SGLT2 inhibitors in cancer: mechanisms of action and therapeutic opportunities","volume":"17","author":"Pandey","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"467","key":"10.1016\/j.ygyno.2026.06.023_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.023_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaoncol.2025.5869","article-title":"Sodium-glucose cotransporter 2 inhibitors for patients with prostate cancer undergoing hormone therapy","volume":"12","author":"Shi","year":"2026","journal-title":"JAMA Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2026.06.023_bb0085","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2026.06.023_bb0090","article-title":"Canagliflozin alleviates progestin resistance by suppressing RARbeta\/CRABP2 signaling in THRB knockout endometrial cancer cells","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.06.023_bb0095","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.7150\/ijms.95584","article-title":"The lower incidence of endometrial cancer after sodium-glucose cotransporter 2 inhibitors administration in type 2 diabetes mellitus population: a nationwide cohort study","volume":"21","author":"Yang","year":"2024","journal-title":"Int. J. Med. Sci."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.023_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, De-identified, federated electronic health record real-world data and analytics network and comparison to the US census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.023_bb0105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"Management of menopausal symptoms","volume":"123","author":"ACOG Practice Bulletin No. 141","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.023_bb0110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/GME.0000000000002415","article-title":"Menopause and the workplace: consensus recommendations from the menopause society","volume":"31","year":"2024","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.023_bb0115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","article-title":"Understanding obesity and endometrial cancer risk: opportunities for prevention","volume":"205","author":"Schmandt","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.06.023_bb0120","article-title":"Obesity and cancer: a translational science review","author":"Shen","year":"2026","journal-title":"JAMA"},{"issue":"35","key":"10.1016\/j.ygyno.2026.06.023_bb0125","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the role of obesity in endometrial cancer risk, prevention, and treatment","volume":"34","author":"Onstad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2026.06.023_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"12","key":"10.1016\/j.ygyno.2026.06.023_bb0135","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes. Rev."},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.023_bb0140","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i7.107335","article-title":"Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and beta-cell function in type 2 diabetes: a meta-analysis","volume":"16","author":"Chai","year":"2025","journal-title":"World J. Diabetes"},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.023_bb0145","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11096-025-01924-0","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis of randomized active-controlled trials","volume":"47","author":"Xu","year":"2025","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.023_bb0150","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s12020-023-03618-x","article-title":"Association of SGLT2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials","volume":"84","author":"Li","year":"2024","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.023_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The Cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.023_bb0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/jnci\/djae023","article-title":"Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis","volume":"116","author":"Suzuki","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.023_bb0165","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajog.2024.07.018","article-title":"Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis","volume":"231","author":"Suzuki","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.023_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","article-title":"Treatment of low-risk endometrial Cancer and complex atypical hyperplasia with the Levonorgestrel-releasing intrauterine device","volume":"131","author":"Pal","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"22","key":"10.1016\/j.ygyno.2026.06.023_bb0175","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1158\/1078-0432.CCR-24-0362","article-title":"Long-term follow-up of Levonorgestrel intrauterine device for atypical hyperplasia and early endometrial Cancer reveals relapse characterized by immune exhaustion","volume":"30","author":"Bowen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.06.023_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1139858","article-title":"Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.023_bb0185","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"issue":"12","key":"10.1016\/j.ygyno.2026.06.023_bb0190","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2021-002699","article-title":"Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis","volume":"31","author":"Chae-Kim","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.023_bb0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.58205","article-title":"GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases","volume":"9","author":"Yen","year":"2026","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.023_bb0200","article-title":"Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"7","author":"Fernandez-Montoli","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.023_bb0205","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3802\/jgo.2014.25.3.214","article-title":"Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia","volume":"25","author":"Shan","year":"2014","journal-title":"J. Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.023_bb0210","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ygyno.2020.02.008","article-title":"The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia\/endometrial intraepithelial neoplasia or endometrial cancer: little impact on response and low live-birth rates","volume":"157","author":"Acosta-Torres","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.023_bb0215","series-title":"Table Describing Changes in Codes for NCI Comorbidity Index","author":"National Cancer Institute","year":"2024"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:36:10Z","timestamp":1786149370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S0090825826020494"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}